This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) projects operating income within $460-$465 million for the second quarter.
IVD Market Sustains Momentum: 3 Stocks in Focus
by Trina Mukherjee
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
Top Research Reports for Adobe, Charter Communications & HCA Healthcare
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Charter Communications (CHTR) and HCA Healthcare (HCA).
Merit Medical Acquires Brightwater Medical for $35 Million
by Zacks Equity Research
The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.
Why Is Becton Dickinson (BDX) Up 3.7% Since Last Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stock Market News For May 9, 2019
by Zacks Equity Research
Wall Street closed mostly lower on Wednesday as trade tensions between the United States and China lingers.
Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.
Becton Dickinson (BDX) Q2 Earnings Beat Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.78% and -0.98%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects BD Medical to drive fiscal Q2 results; foreign exchange headwinds persist.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Celgene, Schlumberger, Becton, Dickinson, Twitter and PPG Industries
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Schlumberger, Becton, Dickinson, Twitter and PPG Industries
Top Analyst Reports for Celgene, Schlumberger & Becton, Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Schlumberger (SLB) and Becton, Dickinson (BDX).
Top Stock Reports for IBM, Honeywell & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Honeywell (HON) and American Express (AXP).
The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors
Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Altria (MO) and Becton, Dickinson (BDX).
BD Introduces New Product to Reduce the Risk of Sepsis
by Zacks Equity Research
BD introduces new FDA cleared product to lower the risk of sepsis and combat platelet contamination.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson (BDX) announces the FDA premarket approval for Venovo venous stent device.
BD Remains Confident About LUTONIX DCB Despite FDA Letter
by Zacks Equity Research
Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.
Stock Market News For Mar 15, 2019
by Zacks Equity Research
Wall Street closed mixed on Thursday as investors??? remained anxious about the delay in sealing a U.S. ??? China trade deal.
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
by Zacks Equity Research
Becton, Dickinson (BDX) receives a number of regulatory approvals of late.
Becton Dickinson (BDX) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.
BD Gains From Solid Global Base, Headwinds Anticipated
by Zacks Equity Research
Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.
The Zacks Analyst Blog Highlights: Procter & Gamble, Becton, Dickinson, Dominion, Chubb and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Becton, Dickinson, Dominion, Chubb and Estee Lauder
Top Analyst Reports for Procter & Gamble, Becton, Dickinson & Dominion Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Becton, Dickinson (BDX) and Dominion Energy (D).